



swissnordicbio

Connecting Healthcare Innovations, Investors & Industry



JÜRIG ZÜRCHER

**Partner, Biotech/Medtech Leader GSA
Ernst & Young**

Jürg's long-standing career with EY has involved extensive audit and corporate finance experience with local and international health/life sciences clients over the past 32 years.

He is currently serving as Lead Audit Partner for Abbott (EPD), AbbVie, CRISPR Therapeutics AG and has served in this role on AC Immune SA, Actelion, BioMedinvest I&II, Evolva, Roche, Santhera Pharmaceuticals, Syngenta, Synthes and HBM Healthcare Investments.

Jürg is the responsible GSA leader for the EY biotech/medtech sector. His rich understanding of the biotech market in the region was instrumental in providing the Swiss federal government with an in-depth analysis of the state of biotechnology in Switzerland and the launch of the 1st Swiss biotechnology report in March 2004.

Since 2004 co-author of the annual Swiss biotech report which is also presented by him for media and the audience of the Swiss Biotech Day. Jürg is also frequent speaker on biotech topics in Switzerland and abroad and lecturer at the Universities of Basel and Lugano on biotech and medtech.

Jürg Zürcher studied at the University of St. Gallen, where he obtained a Master in Business Administration, with focus on auditing. Jürg is a Swiss Certified Accountant.